Viola Maria Popov

Upon successful completion of this activity, you should be better prepared to: Analyze the latest evidence for currently available treatments used in the management of gastric, gastroesophageal junction, and gastroesophageal adenocarcinomas (GEAs) Evaluate emerging clinical trial data for targeted treatment strategies across GEAs Implement strategies to mitigate and manage the adverse events associated with targeted therapy for GEA RELEASE DATE: April 9, 2026 EXPIRATION DATE: April 9, 2027...

Taletrectinib (Ibtrozi) produced enduring responses among patients with ROS1-positive non–small cell lung cancer (NSCLC) who received no prior tyrosine kinase inhibitors (TKIs), according to a presentation of pooled data from the phase 2 TRUST-I (NCT04395677) and TRUST-II trials (NCT04919811) at the 2026 American Association for Cancer Research (AACR) Annual Meeting.

Over the past few years, BCMA-directed bispecific antibodies have evolved into a very significant modality of treatment for patients with early relapse multiple myeloma, and still the treatment paradigm continues to evolve as new phase 3 data, combination approaches, and treatment sequences reveal themselves.